Megestrol acetate (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Megestrol acetate" in English language version.

refsWebsite

Global rank English rank

115nih.gov

4^th place

89doi.org

2^nd place

59books.google.com

3^rd place

21semanticscholar.org

11^th place

8^th place

5worldcat.org

5^th place

2web.archive.org

1^st place

2cnki.com.cn

3,946^th place

6,960^th place

2drugs.com

399^th place

333^rd place

1hormonebalance.org

low place

1aafp.org

1,916^th place

1,419^th place

1seminoncol.org

low place

1kup.at

low place

1justice.gov

918^th place

556^th place

aafp.org

"Choosing Wisely". American Academy of Family Physicians. Retrieved 3 October 2020.

books.google.com

Barakat RR, Markman M, Randall M (2009). Principles and Practice of Gynecologic Oncology. Lippincott Williams & Wilkins. pp. 447–. ISBN 978-0-7817-7845-9.
Marks L (2010). Sexual Chemistry: A History of the Contraceptive Pill. Yale University Press. pp. 77–78. ISBN 978-0-300-16791-7.
Morton IK, Hall JM (1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer. p. 173. ISBN 978-0-7514-0499-9. Retrieved 2 June 2012.
Berger AM, Shuster JL, Von Roenn JH (6 October 2006). Principles And Practice of Palliative Care And Supportive Oncology. Lippincott Williams & Wilkins. p. 128. ISBN 978-0-7817-9595-1. Retrieved 27 May 2012.
Jörres A (19 February 2010). Management of Acute Kidney Problems. Springer. p. 210. ISBN 978-3-540-69413-7. Retrieved 27 May 2012.
Ettinger DS (11 November 2008). Supportive Care in Cancer Therapy. Springer. p. 61. ISBN 978-1-58829-941-3. Retrieved 27 May 2012.
Benign Prostatic Hypertrophy. Springer Science & Business Media. 6 December 2012. pp. 277–. ISBN 978-1-4612-5476-8.
Gordon JD (2007). Obstetrics, Gynecology & Infertility: Handbook for Clinicians. Scrub Hill Press, Inc. pp. 228–. ISBN 978-0-9645467-7-6.
Consolidated List of Products Whose Consumption And/or Sale Have Been Banned, Withdrawn, Severely Restricted Or Not Approved by Governments. United Nations Publications. 1983. pp. 137–. ISBN 978-92-1-130230-1.
FDA Consumer. U.S. Department of Health, Education, and Welfare, Public Health Service, Food and Drug Administration. February 1976. Several foreign countries, including Germany, Canada, and Great Britain, have banned the sale of birth control pills containing megestrol acetate after a study done at FDA's request indicated it caused breast cancer in dogs. Megestrol acetate has never been marketed in the United States as an oral contraceptive. FDA routinely requires long-term animal studies before any drug can be marketed for human use. Following animal studies with megestrol acetate, FDA in the late sixties and early seventies allowed limited studies of the drug in women. In 1972, after noticing a significant number of test dogs developing breast nodules (none of them malignant), FDA ordered that megestrol acetate be discontinued in human oral contraceptive studies.
United States. Congress. Senate. Committee on Labor and Public Welfare (1976). Hearings, Reports and Prints of the Senate Committee on Labor and Public Welfare. U.S. Government Printing Office. Megestrol was never marketed in the United States for contraceptive use because in 1972, FDA took prompt action to discontinue investigational studies on megestrol after dogs exposed to the drug for four years In a chronic toxicity study developed benign breast tumors.
Runnebaum BC, Rabe T, Kiesel L (6 December 2012). Female Contraception: Update and Trends. Springer Science & Business Media. pp. 134–. ISBN 978-3-642-73790-9.
Eibl G, Edderkaoui M (22 April 2015). Risk Factors for Pancreatic Cancer: Underlying Mechanisms and Potential Targets. Frontiers Media SA. pp. 96–. ISBN 978-2-88919-468-1.
Index Nominum 2000: International Drug Directory. Taylor & Francis US. 2000. p. 641. ISBN 978-3-88763-075-1. Retrieved 2 June 2012.
Becker KL (24 April 2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 1195–1196. ISBN 978-0-7817-1750-2. Retrieved 27 May 2012.
Swanton C, Johnston SR (14 November 2011). Handbook of Metastatic Breast Cancer, Second Edition. CRC Press. pp. 18–. ISBN 978-1-84184-812-9.
Marks L (2001). Sexual Chemistry: A History of the Contraceptive Pill. Yale University Press. pp. 78–. ISBN 978-0-300-08943-1.
Unger WP (1 February 1995). "Androgenetic alopecia and its treatment. A historical overview". Hair Transplantation (Third ed.). Taylor & Francis. pp. 1–33. ISBN 978-0-8247-9363-0.
Tejani S, Sanoski C (16 March 2009). Davis's Pocket Clinical Drug Reference. F.A. Davis. pp. 167–. ISBN 978-0-8036-2305-7.
Wirfs MJ (26 July 2017). The APRN's Complete Guide to Prescribing Pediatric Drug Therapy 2. Springer Publishing Company. pp. 18–. ISBN 978-0-8261-6669-2.
Winters SJ, Huhtaniemi IT (25 April 2017). Male Hypogonadism: Basic, Clinical and Therapeutic Principles. Humana Press. pp. 407–. ISBN 978-3-319-53298-1.
Knörr K, Beller FK, Lauritzen C (17 April 2013). Lehrbuch der Gynäkologie. Springer-Verlag. pp. 214–. ISBN 978-3-662-00942-0.
Knörr K, Knörr-Gärtner H, Beller FK, Lauritzen C (8 March 2013). Geburtshilfe und Gynäkologie: Physiologie und Pathologie der Reproduktion. Springer-Verlag. pp. 583–. ISBN 978-3-642-95583-9.
Labhart A (6 December 2012). Clinical Endocrinology: Theory and Practice. Springer Science & Business Media. pp. 554–. ISBN 978-3-642-96158-8.
Horský J, Presl J (1981). "Hormonal Treatment of Disorders of the Menstrual Cycle". In Horsky J, Presl K (eds.). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 309–332. doi:10.1007/978-94-009-8195-9_11. ISBN 978-94-009-8195-9.
Ufer J (1969). The Principles and Practice of Hormone Therapy in Gynaecology and Obstetrics. de Gruyter. p. 49. ISBN 9783110006148. 17α-Hydroxyprogesterone caproate is a depot progestogen which is entirely free of side actions. The dose required to induce secretory changes in primed endometrium is about 250 mg. per menstrual cycle.
Pschyrembel W (1968). Praktische Gynäkologie: für Studierende und Ärzte. Walter de Gruyter. pp. 598, 601. ISBN 978-3-11-150424-7.
Ferin J (September 1972). "Effects, Duration of Action and Metabolism in Man". In Tausk M (ed.). Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents. Vol. II. Pergamon Press. pp. 13–24. ISBN 978-0080168128. OCLC 278011135.
Henzl MR, Edwards JA (10 November 1999). "Pharmacology of Progestins: 17α-Hydroxyprogesterone Derivatives and Progestins of the First and Second Generation". In Sitruk-Ware R, Mishell DR (eds.). Progestins and Antiprogestins in Clinical Practice. Taylor & Francis. pp. 101–132. ISBN 978-0-8247-8291-7.
Brotherton J (1976). Sex Hormone Pharmacology. Academic Press. p. 114. ISBN 978-0-12-137250-7.
Goebelsmann U (1986). "Pharmacokinetics of Contraceptive Steroids in Humans". In Gregoire AT, Blye RP (eds.). Contraceptive Steroids: Pharmacology and Safety. Springer Science & Business Media. pp. 67–111. doi:10.1007/978-1-4613-2241-2_4. ISBN 978-1-4613-2241-2.
Wright JC, Burgess DJ (29 January 2012). Long Acting Injections and Implants. Springer Science & Business Media. pp. 114–. ISBN 978-1-4614-0554-2.
Runnebaum BC, Rabe T, Kiesel L (6 December 2012). Female Contraception: Update and Trends. Springer Science & Business Media. pp. 429–. ISBN 978-3-642-73790-9.
Artini PG, Genazzani AR, Petraglia F (11 December 2001). Advances in Gynecological Endocrinology. CRC Press. pp. 105–. ISBN 978-1-84214-071-0.
King TL, Brucker MC, Kriebs JM, Fahey JO (21 October 2013). Varney's Midwifery. Jones & Bartlett Publishers. pp. 495–. ISBN 978-1-284-02542-2.
Pincus G (3 September 2013). The Control of Fertility. Elsevier. pp. 222–. ISBN 978-1-4832-7088-3.
Denis L (6 December 2012). The Medical Management of Prostate Cancer. Springer Science & Business Media. pp. 45–. ISBN 978-3-642-73238-6.
Karr JP, Yamanaka H (6 December 2012). Prostate Cancer and Bone Metastasis. Springer Science & Business Media. pp. 309–. ISBN 978-1-4615-3398-6.
Foon KA, Muss HB (6 December 2012). Biological and Hormonal Therapies of Cancer. Springer Science & Business Media. pp. 73–. ISBN 978-1-4615-6189-7.
Ratliff TL, Catalona WJ (6 December 2012). Genitourinary Cancer: Basic and Clinical Aspects. Springer Science & Business Media. pp. 171–. ISBN 978-1-4613-2033-3.
El-Etr M, Schumacher M, Baulieu EE (10 November 1999). "Effects of Progesterone and Related Steroids in the Brain". In Régine Sitruk-Ware, Daniel R. Mishell (eds.). Progestins and Antiprogestins in Clinical Practice. Taylor & Francis. pp. 15–58. ISBN 978-0-8247-8291-7. Specific actions of neurosteroids on ion transport across the neuronal plasma membrane have been described (see Fig. 2[10). In hippocampal CA1 neurons, Ffrench Mullen et al. (76) observed an inhibition by PREG, PREGS, and 3α,5β-TH PROG (but not PROG) of both the N- and L-type calcium channel currents, mediated by a pertussis toxin-sensitive G protein mechanism, associated with the activation of protein kinase C. PROG still has no effect on calcium channels of hypothalamic neurons from the ventromedial nucleus; however, the synthetic progestin megestrol acetate inhibits some high-threshold Ca2+ channel currents: not the N-type nor the P-type Ca2+ channel currents, but the residual current. Appetite enhancement induced by megestrol acetate might be partly due to the inhibition of these Ca2+ channel currents, and the attenuation of the firing of ventromedial nucleus neurons, involved in satiety mechanisms (77).
Foon KA (1998). Biological and Hormonal Therapies of Cancer. Springer. p. 73. ISBN 978-0-7923-9997-1. Retrieved 2 June 2012.
Rudel HW, Kincl FA, Henzl MR (1973). Birth Control; Contraception and Abortion. Macmillan. ISBN 9780024044105.
Litwack G (2 December 2012). Biochemical Actions of Hormones. Elsevier. pp. 330–. ISBN 978-0-323-15344-7.
Williams DA, Foye WO, Lemke TL (2002). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 699–. ISBN 978-0-683-30737-5.
Die Gestagene. Springer-Verlag. 27 November 2013. p. 281. ISBN 978-3-642-99941-3.
Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 657–. ISBN 978-1-4757-2085-3.
Buzdar AU (8 November 2007). Endocrine Therapies in Breast Cancer. OUP Oxford. pp. 75–. ISBN 978-0-19-921814-1.
Rose DP (1973). Oral Contraceptives: Psychological and Physiological Effects. Ardent Media. pp. 12–. ISBN 978-0-8422-7101-1.
Statens seruminstitut (Denmark) (1966). Communications: Extraits. Each Delpregnin tablet contains 5 mg megestrol acetate + 0.1 mg mestranol.
Unlisted Drugs. Pharmaceutical Section, Special Libraries Association. 1965.
Modern Veterinary Practice. 1971. Your Q & A concerning megestrol acetate (Oct MVP, p 27), a product containing this compound (Ovarid: Glaxo) has been commercially available for controlling estrus in bitches in the UK for nearly 2 years.
VM/SAC, Veterinary Medicine/small Animal Clinician. Veterinary Medicine Publishing Company. 1977. In England, where megestrol acetate has been marketed for eight years, it is recommended to treat false pregnancy and estrogen-dependent mammary tumors in dogs. It has also been used successfully to treat hypersexuality in male dogs, and miliary dermatitis and eosinophilic granulomas in cats. In 1974, megestrol acetate was approved in the United States for postponement of es- trus and treatment of false pregnancy in dogs.
Upjohn Company (1978). Proceedings of the Symposium on Cheque® for Canine Estrus Prevention, Brook Lodge, Augusta, Michigan, March 13-15, 1978. Upjohn Company. In 1974, Sobering marketed megestrol acetate3 (Figure 1) under the trade name of Ovaban® (Ovarid® in Europe).
Vogelzang N (2006). Comprehensive Textbook of Genitourinary Oncology. Lippincott Williams & Wilkins. pp. 317–. ISBN 978-0-7817-4984-8.
Kinzbrunner B, Weinreb NJ, Policzer JS (2002). 20 Common Problems: End-of-Life Care. McGraw Hill Professional. ISBN 978-0-07-034883-7.
Unzeitig V, van Lunsen RH (15 February 2000). Contraceptive Choices and Realities: Proceedings of the 5th Congress of the European Society of Contraception. CRC Press. pp. 73–. ISBN 978-1-85070-067-8.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, World Health Organization, International Agency for Research on Cancer (2007). Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. World Health Organization. p. 44. ISBN 978-92-832-1291-1.
Beaver BV (1 January 2009). Canine Behavior: Insights and Answers. Elsevier Health Sciences. pp. 128–. ISBN 978-1-4160-5419-1.

cnki.com.cn

en.cnki.com.cn

Chu YH, Li Q, Zhao ZF (April 1986). "Pharmacokinetics of megestrol acetate in women receiving IM injection of estradiol-megestrol long-acting injectable contraceptive". The Chinese Journal of Clinical Pharmacology. Archived from the original on 25 May 2021. Retrieved 14 August 2019. A radioimmunoassay (RIA), radioligand assay and equilibrium dialysis for determination of plasma and salivary megestrol acetate (MA) concentration, sex hormone binding globulin (SHBG) capacity in plasma and percentage albumin bound MA were studied in healthy women receiving single im injection of estradiol-megestrol long-acting injectable contraceptive. The results showed that after injection the concentration of plasma MA increased rapidly. The meantime of peak plasma MA level was 3rd day, there was a linear relationship between log of plasma MA concentration and time (day) after administration in all subjects, elimination phase half-life t1/2β = 14.35 ± 9.1 days. The plasma sex hormone-binding globulin capacity significantly increased at 7th, 14th day and decreased at 21st, 29th day after injection. The percentage albumin bound MA was 82.4%. There was no specific sex hormone-binding globulin bound MA. There was a positive correlation between the MA concentrations in saliva and those in plasma.
Chu YH, Li Q, Zhao ZF (April 1986). "Pharmacokinetics of megestrol acetate in women receiving IM injection of estradiol-megestrol long-acting injectable contraceptive". The Chinese Journal of Clinical Pharmacology. The results showed that after injection the concentration of plasma MA increased rapidly. The meantime of peak plasma MA level was 3rd day, there was a linear relationship between log of plasma MA concentration and time (day) after administration in all subjects, elimination phase half-life t1/2β = 14.35 ± 9.1 days.

doi.org

Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. (December 2003). "Classification and pharmacology of progestins". Maturitas. 46 (Suppl 1): S7–S16. doi:10.1016/j.maturitas.2003.09.014. PMID 14670641.
Canetta R, Florentine S, Hunter H, Lenaz L (September 1983). "Megestrol acetate". Cancer Treatment Reviews. 10 (3): 141–157. doi:10.1016/0305-7372(83)90029-4. PMID 6352021.
Schacter L, Rozencweig M, Canetta R, Kelley S, Nicaise C, Smaldone L (March 1989). "Megestrol acetate: clinical experience". Cancer Treatment Reviews. 16 (1): 49–63. doi:10.1016/0305-7372(89)90004-2. PMID 2471590.
Mears E (May 1963). "A new type of oral contraceptive". British Medical Journal. 1 (5341): 1318–1320. doi:10.1136/bmj.1.5341.1318. PMC 2123904. PMID 13934321.
Nelson LW, Weikel JH, Reno FE (October 1973). "Mammary nodules in dogs during four years' treatment with megestrol acetate or chlormadinone acetate". Journal of the National Cancer Institute. 51 (4): 1303–1311. doi:10.1093/jnci/51.4.1303. PMID 4126857.
Taylor JK, Pendleton N (September 2016). "Progesterone therapy for the treatment of non-cancer cachexia: a systematic review". BMJ Supportive & Palliative Care. 6 (3): 276–286. doi:10.1136/bmjspcare-2015-001041. PMID 27098973.
Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S (March 2013). "Megestrol acetate for treatment of anorexia-cachexia syndrome". The Cochrane Database of Systematic Reviews. 2013 (3): CD004310. doi:10.1002/14651858.CD004310.pub3. PMC 6418472. PMID 23543530.
Loprinzi C, Jatoi A (April 2006). "Antiemetic properties of megestrol acetate". Journal of Palliative Medicine. 9 (2): 239–240. doi:10.1089/jpm.2006.9.239. PMID 16629544.
Zang J, Hou M, Gou HF, Qiu M, Wang J, Zhou XJ, et al. (May 2011). "Antiemetic activity of megestrol acetate in patients receiving chemotherapy". Supportive Care in Cancer. 19 (5): 667–673. doi:10.1007/s00520-010-0886-x. PMID 20419494. S2CID 24567093.
Newton JR, D'arcangues C, Hall PE (1994). "A review of "once-a-month" combined injectable contraceptives". Journal of Obstetrics and Gynaecology. 4 (Suppl 1): S1-34. doi:10.3109/01443619409027641. PMID 12290848.
Kauppila A, Kivinen S, Leinonen P, Tuimala R, Vihko R, Ylöstalo P (1983). "Comparison of megestrol acetate and clomiphene citrate as supplemental medication in postmenopausal oestrogen replacement therapy". Archives of Gynecology. 234 (1): 49–58. doi:10.1007/bf02114725. PMID 6660928. S2CID 31075984.
Erlik Y, Meldrum DR, Lagasse LD, Judd HL (August 1981). "Effect of megestrol acetate on flushing and bone metabolism in post-menopausal women". Maturitas. 3 (2): 167–172. doi:10.1016/0378-5122(81)90008-6. PMID 7289887.
Farish E, Barnes JF, O'Donoghue F, Fletcher CD, Ekevall K, Hart DM (June 2000). "The role of megestrol acetate as an alternative to conventional hormone replacement therapy". Climacteric. 3 (2): 125–134. doi:10.3109/13697130009167614. PMID 11910653. S2CID 19267190.
Loprinzi CL, Michalak JC, Quella SK, O'Fallon JR, Hatfield AK, Nelimark RA, et al. (August 1994). "Megestrol acetate for the prevention of hot flashes". The New England Journal of Medicine. 331 (6): 347–352. doi:10.1056/NEJM199408113310602. PMID 8028614.
Frisk J (January 2010). "Managing hot flushes in men after prostate cancer--a systematic review". Maturitas. 65 (1): 15–22. doi:10.1016/j.maturitas.2009.10.017. PMID 19962840.
Bertelli G, Venturini M, Del Mastro L, Bergaglio M, Sismondi P, Biglia N, et al. (June 2002). "Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study". Annals of Oncology. 13 (6): 883–888. doi:10.1093/annonc/mdf151. PMID 12123333.
Ostergaard E (February 1965). "The oral progestational and anti-ovulatory properties of megestrol acetate and its therapeutic use in gynaecological disorders". The Journal of Obstetrics and Gynaecology of the British Empire. 72 (1): 45–48. doi:10.1111/j.1471-0528.1965.tb01372.x. PMID 12332461. S2CID 72608039.
Gal D, Edman CD, Vellios F, Forney JP (June 1983). "Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia". American Journal of Obstetrics and Gynecology. 146 (3): 316–322. doi:10.1016/0002-9378(83)90754-8. PMID 6859142.
Veenhof CH, van der Burg ME, Nooy M, Aalders JG, Pecorelli S, Oliveira CF, et al. (1994). "Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma". European Journal of Cancer. 30A (5): 697–698. doi:10.1016/0959-8049(94)90548-7. PMID 8080689.
Geller J, Albert J, Yen SS (November 1978). "Treatment of advanced cancer of prostate with megestrol acetate". Urology. 12 (5): 537–541. doi:10.1016/0090-4295(78)90467-3. PMID 153029.
Block M, Bonomi P, Anderson K, Wolter J, Showel J, Pessis D, et al. (1981). "Treatment of stage D prostatic carcinoma with megestrol acetate". Journal of Surgical Oncology. 17 (4): 367–371. doi:10.1002/jso.2930170409. PMID 7265976. S2CID 72595843.
Geller J, Albert J, Yen SS, Geller S, Loza D (March 1981). "Medical castration of males with megestrol acetate and small doses of diethylstilbestrol". The Journal of Clinical Endocrinology and Metabolism. 52 (3): 576–580. doi:10.1210/jcem-52-3-576. PMID 6161942.
Johnson DE, Kaesler KE, Ayala AG (1975). "Megestrol acetate for treatment of advanced carcinoma of the prostate". Journal of Surgical Oncology. 7 (1): 9–15. doi:10.1002/jso.2930070103. PMID 1177459. S2CID 20882018.
Lebech PE, Nordentoft EL (1967). "A study of endocrine function in the treatment of benign prostatic hypertrophy with megestrol acetate". Acta Obstetricia et Gynecologica Scandinavica. 46 (S9): 25–38. doi:10.3109/00016346709156833. PMID 4169449. S2CID 44780569.
Donkervoort T, Zinner NR, Sterling AM, Donker PJ, Van Ness J, Ritter RC (November 1975). "Megestrol acetate in treatment of benign prostatic hypertrophy". Urology. 6 (5): 580–587. doi:10.1016/0090-4295(75)90506-3. PMID 52933.
Mitsuyasu R, Bonomi P, Anderson K, Fischer W (May 1981). "Response to megestrol in male breast carcinoma". Archives of Internal Medicine. 141 (6): 809–810. doi:10.1001/archinte.1981.00340060117031. PMID 6263202.
Loprinzi CL, Bernath AM, Schaid DJ, Malliard JA, Athmann LM, Michalak JC, et al. (October 1994). "Phase III evaluation of 4 doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia". Oncology. 51 (Suppl 1): 2–7. doi:10.1159/000227407. PMID 7970505.
Willemse PH, van der Ploeg E, Sleijfer DT, Tjabbes T, van Veelen H (March 1990). "A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer". European Journal of Cancer. 26 (3): 337–343. doi:10.1016/0277-5379(90)90231-h. PMID 2141491.
Gullett NP, Hebbar G, Ziegler TR (April 2010). "Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting". The American Journal of Clinical Nutrition. 91 (4): 1143S–1147S. doi:10.3945/ajcn.2010.28608E. PMC 2844687. PMID 20164318.
Wermers RA, Hurley DL, Kearns AE (December 2004). "Osteoporosis associated with megestrol acetate". Mayo Clinic Proceedings. 79 (12): 1557–1561. doi:10.4065/79.12.1557. PMID 15595341.
Cuerda C, Zugasti A, Bretón I, Camblor M, Miralles P, García P (February 2005). "Treatment with nandrolone decanoate and megestrol acetate in HIV-infected men". Nutrition in Clinical Practice. 20 (1): 93–97. doi:10.1177/011542650502000193. PMID 16207650.
Mulligan K, Zackin R, Von Roenn JH, Chesney MA, Egorin MJ, Sattler FR, et al. (February 2007). "Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial". The Journal of Clinical Endocrinology and Metabolism. 92 (2): 563–570. doi:10.1210/jc.2006-0954. PMID 17090640.
Casaburi R, Nakata J, Bistrong L, Torres E, Rambod M, Porszasz J (November 2015). "Effect of Megestrol Acetate and Testosterone on Body Composition and Hormonal Responses in COPD Cachexia". Chronic Obstructive Pulmonary Diseases. 3 (1): 389–397. doi:10.15326/jcopdf.3.1.2015.0128. PMC 5559120. PMID 28848861.
Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinung M (1997). "Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature". Archives of Internal Medicine. 157 (15): 1651–1656. doi:10.1001/archinte.1997.00440360053005. PMID 9250225.
Chidakel AR, Zweig SB, Schlosser JR, Homel P, Schappert JW, Fleckman AM (February 2006). "High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate". Journal of Endocrinological Investigation. 29 (2): 136–140. doi:10.1007/bf03344086. PMID 16610239. S2CID 25440558.
Bulchandani D, Nachnani J, Amin A, May J (August 2008). "Megestrol acetate-associated adrenal insufficiency". The American Journal of Geriatric Pharmacotherapy. 6 (3): 167–172. doi:10.1016/j.amjopharm.2008.08.004. PMID 18775392.
Foitl DR, Hyman G, Lefkowitch JH (February 1989). "Jaundice and intrahepatic cholestasis following high-dose megestrol acetate for breast cancer". Cancer. 63 (3): 438–439. doi:10.1002/1097-0142(19890201)63:3<438::aid-cncr2820630307>3.0.co;2-o. PMID 2912522. S2CID 35300388.
Gruber T, Dare AO, Balos LL, Lele S, Fenstermaker RA (February 2004). "Multiple meningiomas arising during long-term therapy with the progesterone agonist megestrol acetate. Case report". Journal of Neurosurgery. 100 (2): 328–331. doi:10.3171/jns.2004.100.2.0328. PMID 15086241.
Gruber TJ, Fabiano AJ, Deeb G, Lele SB, Fenstermaker RA (November 2011). "Intracranial meningiomas in patients with uterine sarcoma treated with long-term megestrol acetate therapy". World Neurosurgery. 76 (5): 477.e16–477.e20. doi:10.1016/j.wneu.2011.03.035. PMID 22152580.
Schindler AE (2015). "Pharmacology of Progestogens". Progestogens in Obstetrics and Gynecology. Springer. pp. 33–40. doi:10.1007/978-3-319-14385-9_2. ISBN 978-3-319-14384-2. S2CID 85844034.
Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. (2008). "Classification and pharmacology of progestins". Maturitas. 61 (1–2): 171–180. doi:10.1016/j.maturitas.2008.11.013. PMID 19434889.
Horský J, Presl J (1981). "Hormonal Treatment of Disorders of the Menstrual Cycle". In Horsky J, Presl K (eds.). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 309–332. doi:10.1007/978-94-009-8195-9_11. ISBN 978-94-009-8195-9.
Sang GW (April 1994). "Pharmacodynamic effects of once-a-month combined injectable contraceptives". Contraception. 49 (4): 361–385. doi:10.1016/0010-7824(94)90033-7. PMID 8013220.
Toppozada MK (April 1994). "Existing once-a-month combined injectable contraceptives". Contraception. 49 (4): 293–301. doi:10.1016/0010-7824(94)90029-9. PMID 8013216.
Goebelsmann U (1986). "Pharmacokinetics of Contraceptive Steroids in Humans". In Gregoire AT, Blye RP (eds.). Contraceptive Steroids: Pharmacology and Safety. Springer Science & Business Media. pp. 67–111. doi:10.1007/978-1-4613-2241-2_4. ISBN 978-1-4613-2241-2.
Becker H, Düsterberg B, Klosterhalfen H (1980). "[Bioavailability of cyproterone acetate after oral and intramuscular application in men (author's transl)]" [Bioavailability of Cyproterone Acetate after Oral and Intramuscular Application in Men]. Urologia Internationalis. 35 (6): 381–385. doi:10.1159/000280353. PMID 6452729.
Moltz L, Haase F, Schwartz U, Hammerstein J (May 1983). "[Treatment of virilized women with intramuscular administration of cyproterone acetate]" [Efficacy of Intra muscularly Applied Cyproterone Acetate in Hyperandrogenism]. Geburtshilfe und Frauenheilkunde. 43 (5): 281–287. doi:10.1055/s-2008-1036893. PMID 6223851.
Lundgren S, Lønning PE, Utaaker E, Aakvaag A, Kvinnsland S (June 1990). "Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer--I. General findings". Journal of Steroid Biochemistry. 36 (1–2): 99–104. doi:10.1016/0022-4731(90)90118-c. PMID 2362454.
Geller J, Albert J, Geller S (1982). "Acute therapy with megestrol acetate decreases nuclear and cytosol androgen receptors in human BPH tissue". The Prostate. 3 (1): 11–15. doi:10.1002/pros.2990030103. PMID 6176985. S2CID 23541558.
Alexieva-Figusch J, Blankenstein MA, de Jong FH, Lamberts SW (September 1984). "Endocrine effects of the combination of megestrol acetate and tamoxifen in the treatment of metastatic breast cancer". European Journal of Cancer & Clinical Oncology. 20 (9): 135–140. doi:10.1016/0277-5379(84)90121-4. PMID 6434315.
Endrikat J, Gerlinger C, Richard S, Rosenbaum P, Düsterberg B (December 2011). "Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide". Contraception. 84 (6): 549–557. doi:10.1016/j.contraception.2011.04.009. PMID 22078182.
Vessey M, Mears E, Andolšek L, Ogrinc-Oven M (1972). "Randomised double-blind trial of four oral progestagen-only contraceptives". The Lancet. 299 (7757): 915–922. doi:10.1016/S0140-6736(72)91492-4. ISSN 0140-6736.
Smith JA (January 1987). "New methods of endocrine management of prostatic cancer". The Journal of Urology. 137 (1): 1–10. doi:10.1016/s0022-5347(17)43855-9. PMID 3540320.
Johnson DE, Babaian RJ, Swanson DA, von Eschenbach AC, Wishnow KI, Tenney D (May 1988). "Medical castration using megestrol acetate and minidose estrogen". Urology. 31 (5): 371–374. doi:10.1016/0090-4295(88)90726-1. PMID 3284149.
Geller J (September 1988). "Megestrol acetate and minidose estrogen in prostatic carcinoma". Urology. 32 (3): 281–283. doi:10.1016/0090-4295(88)90402-5. PMID 3413920.
Geller J (February 1991). "Megestrol acetate plus low-dose estrogen in the management of advanced prostatic carcinoma". The Urologic Clinics of North America. 18 (1): 83–91. doi:10.1016/S0094-0143(21)01395-1. PMID 1825145.
Pommier RF, Woltering EA, Fletcher WS (December 1994). "Changes in serum sex steroid levels during megestrol acetate therapy". Surgical Oncology. 3 (6): 351–359. doi:10.1016/0960-7404(94)90074-4. PMID 7773452.
Lønning PE (2009). "Additive endocrine therapy for advanced breast cancer - back to the future". Acta Oncologica. 48 (8): 1092–1101. doi:10.3109/02841860903117816. PMID 19863216. S2CID 26081050.
Eil C, Edelson SK (July 1984). "The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors". The Journal of Clinical Endocrinology and Metabolism. 59 (1): 51–55. doi:10.1210/jcem-59-1-51. PMID 6725525.
Luthy IA, Begin DJ, Labrie F (November 1988). "Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture". Journal of Steroid Biochemistry. 31 (5): 845–852. doi:10.1016/0022-4731(88)90295-6. PMID 2462135.
Poyet P, Labrie F (October 1985). "Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate". Molecular and Cellular Endocrinology. 42 (3): 283–288. doi:10.1016/0303-7207(85)90059-0. PMID 3930312. S2CID 24746807.
Farrar DJ (March 1999). "Megestrol acetate: promises and pitfalls". AIDS Patient Care and STDs. 13 (3): 149–152. doi:10.1089/apc.1999.13.149. PMID 10375262.
Tisell LE, Salander H (February 1975). "Androgenic properties and adrenal depressant activity of megestrol acetate observed in castrated male rats". Acta Endocrinologica. 78 (2): 316–324. doi:10.1530/acta.0.0780316. PMID 1172901.
El Makhzangy MN, Wynn V, Lawrence DM (January 1979). "Sex hormone binding globulin capacity as an index of oestrogenicity or androgenicity in women on oral contraceptive steroids". Clinical Endocrinology. 10 (1): 39–45. doi:10.1111/j.1365-2265.1979.tb03031.x. PMID 571314. S2CID 7262495.
Labrie C, Cusan L, Plante M, Lapointe S, Labrie F (October 1987). "Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer". Journal of Steroid Biochemistry. 28 (4): 379–384. doi:10.1016/0022-4731(87)91054-5. PMID 2444770.
Briggs MH, Briggs M (October 1973). "Glucocorticoid properties of progestogens". Steroids. 22 (4): 555–559. doi:10.1016/0039-128x(73)90011-1. PMID 4747450.
Helle SI, Lundgren S, Geisler S, Ekse D, Holly JM, Lønning PE (July 1999). "Effects of treatment with megestrol acetate on the insulin-like growth factor system: time and dose dependency". European Journal of Cancer. 35 (7): 1070–1075. doi:10.1016/s0959-8049(99)00055-6. PMID 10533450.
Stanczyk FZ (September 2002). "Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception". Reviews in Endocrine & Metabolic Disorders. 3 (3): 211–224. doi:10.1023/A:1020072325818. PMID 12215716. S2CID 27018468.
Goletiani NV, Keith DR, Gorsky SJ (October 2007). "Progesterone: review of safety for clinical studies". Experimental and Clinical Psychopharmacology. 15 (5): 427–444. doi:10.1037/1064-1297.15.5.427. PMID 17924777.
Farinha A, Bica A, Tavares P (May 2000). "Improved bioavailability of a micronized megestrol acetate tablet formulation in humans". Drug Development and Industrial Pharmacy. 26 (5): 567–570. doi:10.1081/ddc-100101270. PMID 10789071. S2CID 24952875.
Gadducci A, Genazzani AR (December 1999). "Endocrine therapy for gynecological cancer". Gynecological Endocrinology. 13 (6): 441–456. doi:10.3109/09513599909167590. PMID 10685337.
Pirzada OL (June 2002). "Effect of megestrol caproate on the reproductive function of laboratory animals". Bulletin of Experimental Biology and Medicine. 133 (6): 574–576. doi:10.1023/A:1020233925626. PMID 12447469. S2CID 24115315.
Ringold HJ, Ruelas JP, Batres E, Djerassi C (1959). "Steroids. CXVIII.16-Methyl Derivatives of 17α-Hydroxyprogesterone and of Reichstein's Substance "S"". Journal of the American Chemical Society. 81 (14): 3712–3716. doi:10.1021/ja01523a055. ISSN 0002-7863.
Cooley G, Kellie AE (October 1964). "Synthesis of [1,2-3H2]medroxyprogesterone acetate (17-alpha-acetoxy-6-alpha-methyl[1,2-3H2]pregn-4-ene-3,20-dione) and [1,2-3H2]megestrol acetate (17-alpha-acetoxy-6-methyl[1,2-3H2]pregna-4,6-diene-3,20-dione)". The Biochemical Journal. 93 (1): 8C–9C. doi:10.1042/bj0930008c. PMID 5320316.
Bakke OM, Wardell WM, Lasagna L (May 1984). "Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: issues of safety". Clinical Pharmacology and Therapeutics. 35 (5): 559–567. doi:10.1038/clpt.1984.78. PMID 6713769. S2CID 7452111.
Kistner RW (1959). "Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium". Cancer. 12 (6): 1106–1122. doi:10.1002/1097-0142(195911/12)12:6<1106::aid-cncr2820120607>3.0.co;2-m. PMID 14409476.
Geisler HE (1973). "The use of megestrol acetate in the treatment of advanced malignant lesions of the endometrium". Gynecologic Oncology. 1 (4): 340–344. doi:10.1016/0090-8258(73)90026-7. ISSN 0090-8258.
Lundgren S (1992). "Progestins in breast cancer treatment. A review". Acta Oncologica. 31 (7): 709–722. doi:10.3109/02841869209083859. PMID 1476750.
Taylor SG, Morris RS (January 1951). "Hormones in breast metastasis therapy". The Medical Clinics of North America. 35 (1): 51–61. doi:10.1016/s0025-7125(16)35321-4. PMID 14796108.
Gordon D, Horwitt BN, Segaloff A, Murison PJ, Schlosser JV (March 1952). "Hormonal therapy in cancer of the breast. III. Effect of progesterone on clinical course and hormonal excretion". Cancer. 5 (2): 275–277. doi:10.1002/1097-0142(195203)5:2<275::aid-cncr2820050213>3.0.co;2-h. PMID 14905411.
Stoll BA (August 1967). "Progestin therapy of breast cancer: comparison of agents". British Medical Journal. 3 (5561): 338–341. doi:10.1136/bmj.3.5561.338. PMC 1841969. PMID 6029163.
Ansfield FJ, Davis HL, Ellerby RA, Ramirez G (April 1974). "A clinical trial of megestrol acetate in advanced breast cancer". Cancer. 33 (4): 907–910. doi:10.1002/1097-0142(197404)33:4<907::aid-cncr2820330403>3.0.co;2-y. PMID 4819220. S2CID 45772720.
Alexieva-Figusch J, van Gilse HA, Hop WC, Phoa CH, Blonk-van der Wijst J, Treurniet RE (December 1980). "Progestin therapy in advanced breast cancer: megestrol acetate--an evaluation of 160 treated cases". Cancer. 46 (11): 2369–2372. doi:10.1002/1097-0142(19801201)46:11<2369::aid-cncr2820461111>3.0.co;2-3. PMID 7438013. S2CID 39767759.
Bines J, Dienstmann R, Obadia RM, Branco LG, Quintella DC, Castro TM, et al. (April 2014). "Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial". Annals of Oncology. 25 (4): 831–836. doi:10.1093/annonc/mdu015. PMID 24615412.
Gutierrez R (August 1949). "New horizons in the surgical management of carcinoma of the prostate gland". American Journal of Surgery. 78 (2): 147–169. doi:10.1016/0002-9610(49)90323-2. PMID 18135629.
Tchekmedyian NS, Tait N, Moody M, Aisner J (March 1987). "High-dose megestrol acetate. A possible treatment for cachexia". JAMA. 257 (9): 1195–1198. doi:10.1001/jama.1987.03390090067026. PMID 3806918.
Frick J (1973). "Control of spermatogenesis in men by combined administration of progestin and androgen". Contraception. 8 (3): 191–206. doi:10.1016/0010-7824(73)90030-9. ISSN 0010-7824.
Simpson BS, Papich MG (March 2003). "Pharmacologic management in veterinary behavioral medicine". The Veterinary Clinics of North America. Small Animal Practice. 33 (2): 365–404, vii. doi:10.1016/S0195-5616(02)00130-4. PMID 12701517.

drugs.com

hormonebalance.org

Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.

justice.gov

"Par Pharmaceutical Companies Inc. Pleads Guilty, Admits Misbranding Of Megace ES". Offices of the United States Attorneys. 18 March 2015. Retrieved 3 October 2020.

kup.at

Kuhl H (2011). "Pharmacology of progestogens" (PDF). Journal für Reproduktionsmedizin und Endokrinologie-Journal of Reproductive Medicine and Endocrinology. 8 (Special Issue 1): 157–176.

nih.gov

pubmed.ncbi.nlm.nih.gov

Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. (December 2003). "Classification and pharmacology of progestins". Maturitas. 46 (Suppl 1): S7–S16. doi:10.1016/j.maturitas.2003.09.014. PMID 14670641.
Canetta R, Florentine S, Hunter H, Lenaz L (September 1983). "Megestrol acetate". Cancer Treatment Reviews. 10 (3): 141–157. doi:10.1016/0305-7372(83)90029-4. PMID 6352021.
Schacter L, Rozencweig M, Canetta R, Kelley S, Nicaise C, Smaldone L (March 1989). "Megestrol acetate: clinical experience". Cancer Treatment Reviews. 16 (1): 49–63. doi:10.1016/0305-7372(89)90004-2. PMID 2471590.
Mears E (May 1963). "A new type of oral contraceptive". British Medical Journal. 1 (5341): 1318–1320. doi:10.1136/bmj.1.5341.1318. PMC 2123904. PMID 13934321.
Nelson LW, Weikel JH, Reno FE (October 1973). "Mammary nodules in dogs during four years' treatment with megestrol acetate or chlormadinone acetate". Journal of the National Cancer Institute. 51 (4): 1303–1311. doi:10.1093/jnci/51.4.1303. PMID 4126857.
Taylor JK, Pendleton N (September 2016). "Progesterone therapy for the treatment of non-cancer cachexia: a systematic review". BMJ Supportive & Palliative Care. 6 (3): 276–286. doi:10.1136/bmjspcare-2015-001041. PMID 27098973.
Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S (March 2013). "Megestrol acetate for treatment of anorexia-cachexia syndrome". The Cochrane Database of Systematic Reviews. 2013 (3): CD004310. doi:10.1002/14651858.CD004310.pub3. PMC 6418472. PMID 23543530.
Loprinzi C, Jatoi A (April 2006). "Antiemetic properties of megestrol acetate". Journal of Palliative Medicine. 9 (2): 239–240. doi:10.1089/jpm.2006.9.239. PMID 16629544.
Zang J, Hou M, Gou HF, Qiu M, Wang J, Zhou XJ, et al. (May 2011). "Antiemetic activity of megestrol acetate in patients receiving chemotherapy". Supportive Care in Cancer. 19 (5): 667–673. doi:10.1007/s00520-010-0886-x. PMID 20419494. S2CID 24567093.
Sedlacek SM (April 1988). "An overview of megestrol acetate for the treatment of advanced breast cancer". Seminars in Oncology. 15 (2 Suppl 1): 3–13. PMID 3285483.
Newton JR, D'arcangues C, Hall PE (1994). "A review of "once-a-month" combined injectable contraceptives". Journal of Obstetrics and Gynaecology. 4 (Suppl 1): S1-34. doi:10.3109/01443619409027641. PMID 12290848.
Kauppila A, Kivinen S, Leinonen P, Tuimala R, Vihko R, Ylöstalo P (1983). "Comparison of megestrol acetate and clomiphene citrate as supplemental medication in postmenopausal oestrogen replacement therapy". Archives of Gynecology. 234 (1): 49–58. doi:10.1007/bf02114725. PMID 6660928. S2CID 31075984.
Erlik Y, Meldrum DR, Lagasse LD, Judd HL (August 1981). "Effect of megestrol acetate on flushing and bone metabolism in post-menopausal women". Maturitas. 3 (2): 167–172. doi:10.1016/0378-5122(81)90008-6. PMID 7289887.
Farish E, Barnes JF, O'Donoghue F, Fletcher CD, Ekevall K, Hart DM (June 2000). "The role of megestrol acetate as an alternative to conventional hormone replacement therapy". Climacteric. 3 (2): 125–134. doi:10.3109/13697130009167614. PMID 11910653. S2CID 19267190.
Loprinzi CL, Michalak JC, Quella SK, O'Fallon JR, Hatfield AK, Nelimark RA, et al. (August 1994). "Megestrol acetate for the prevention of hot flashes". The New England Journal of Medicine. 331 (6): 347–352. doi:10.1056/NEJM199408113310602. PMID 8028614.
Guise TA, Oefelein MG, Eastham JA, Cookson MS, Higano CS, Smith MR (2007). "Estrogenic side effects of androgen deprivation therapy". Reviews in Urology. 9 (4): 163–180. PMC 2213888. PMID 18231613.
Frisk J (January 2010). "Managing hot flushes in men after prostate cancer--a systematic review". Maturitas. 65 (1): 15–22. doi:10.1016/j.maturitas.2009.10.017. PMID 19962840.
Bertelli G, Venturini M, Del Mastro L, Bergaglio M, Sismondi P, Biglia N, et al. (June 2002). "Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study". Annals of Oncology. 13 (6): 883–888. doi:10.1093/annonc/mdf151. PMID 12123333.
Ostergaard E (February 1965). "The oral progestational and anti-ovulatory properties of megestrol acetate and its therapeutic use in gynaecological disorders". The Journal of Obstetrics and Gynaecology of the British Empire. 72 (1): 45–48. doi:10.1111/j.1471-0528.1965.tb01372.x. PMID 12332461. S2CID 72608039.
Palti Z (August 1966). "Clinical results of treatment with megestrol acetate in menstrual disorders and contraception". The Indian Practitioner. 19 (8): 597–600. PMID 5916119.
Schlaff WD, Dugoff L, Damewood MD, Rock JA (April 1990). "Megestrol acetate for treatment of endometriosis". Obstetrics and Gynecology. 75 (4): 646–648. PMID 2314784.
Gal D, Edman CD, Vellios F, Forney JP (June 1983). "Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia". American Journal of Obstetrics and Gynecology. 146 (3): 316–322. doi:10.1016/0002-9378(83)90754-8. PMID 6859142.
Geisler HE (January 1983). "Megestrol acetate for the palliation of advanced ovarian carcinoma". Obstetrics and Gynecology. 61 (1): 95–98. PMID 6185891.
Geisler HE (March 1985). "The use of high-dose megestrol acetate in the treatment of ovarian adenocarcinoma". Seminars in Oncology. 12 (1 Suppl 1): 20–22. PMID 3975647.
Sikic BI, Scudder SA, Ballon SC, Soriero OM, Christman JE, Suey L, et al. (December 1986). "High-dose megestrol acetate therapy of ovarian carcinoma: a phase II study by the Northern California Oncology Group". Seminars in Oncology. 13 (4 Suppl 4): 26–32. PMID 3099393.
Veenhof CH, van der Burg ME, Nooy M, Aalders JG, Pecorelli S, Oliveira CF, et al. (1994). "Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma". European Journal of Cancer. 30A (5): 697–698. doi:10.1016/0959-8049(94)90548-7. PMID 8080689.
Frick J, Marberger H, Swoboda HP (May 1971). "[Hormone therapy of prostatic neoplasms]". Der Urologe (in German). 10 (3): 117–119. PMID 4104209.
Geller J, Albert J, Yen SS (November 1978). "Treatment of advanced cancer of prostate with megestrol acetate". Urology. 12 (5): 537–541. doi:10.1016/0090-4295(78)90467-3. PMID 153029.
Block M, Bonomi P, Anderson K, Wolter J, Showel J, Pessis D, et al. (1981). "Treatment of stage D prostatic carcinoma with megestrol acetate". Journal of Surgical Oncology. 17 (4): 367–371. doi:10.1002/jso.2930170409. PMID 7265976. S2CID 72595843.
Geller J, Albert J, Yen SS, Geller S, Loza D (March 1981). "Medical castration of males with megestrol acetate and small doses of diethylstilbestrol". The Journal of Clinical Endocrinology and Metabolism. 52 (3): 576–580. doi:10.1210/jcem-52-3-576. PMID 6161942.
Geller J, Albert J, Yen SS, Geller S, Loza D (April 1981). "Medical castration with megestrol acetate and minidose of diethylstilbestrol". Urology. 17 (4 Suppl): 27–33. PMID 6782738.
Johnson DE, Kaesler KE, Ayala AG (1975). "Megestrol acetate for treatment of advanced carcinoma of the prostate". Journal of Surgical Oncology. 7 (1): 9–15. doi:10.1002/jso.2930070103. PMID 1177459. S2CID 20882018.
Bonomi P, Pessis D, Bunting N, Block M, Anderson K, Wolter J, et al. (March 1985). "Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer". Seminars in Oncology. 12 (1 Suppl 1): 36–39. PMID 3975650.
Lebech PE, Nordentoft EL (1967). "A study of endocrine function in the treatment of benign prostatic hypertrophy with megestrol acetate". Acta Obstetricia et Gynecologica Scandinavica. 46 (S9): 25–38. doi:10.3109/00016346709156833. PMID 4169449. S2CID 44780569.
Donkervoort T, Zinner NR, Sterling AM, Donker PJ, Van Ness J, Ritter RC (November 1975). "Megestrol acetate in treatment of benign prostatic hypertrophy". Urology. 6 (5): 580–587. doi:10.1016/0090-4295(75)90506-3. PMID 52933.
Mitsuyasu R, Bonomi P, Anderson K, Fischer W (May 1981). "Response to megestrol in male breast carcinoma". Archives of Internal Medicine. 141 (6): 809–810. doi:10.1001/archinte.1981.00340060117031. PMID 6263202.
Cai DP, Ji ZY, Shi YM (October 2001). "[Clinical study on treatment of female idiopathic precocious puberty with combined therapy of Chinese medicine and megestrol acetate]". Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi = Chinese Journal of Integrated Traditional and Western Medicine (in Chinese). 21 (10): 732–735. PMID 12575602.
Loprinzi CL, Bernath AM, Schaid DJ, Malliard JA, Athmann LM, Michalak JC, et al. (October 1994). "Phase III evaluation of 4 doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia". Oncology. 51 (Suppl 1): 2–7. doi:10.1159/000227407. PMID 7970505.
Willemse PH, van der Ploeg E, Sleijfer DT, Tjabbes T, van Veelen H (March 1990). "A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer". European Journal of Cancer. 26 (3): 337–343. doi:10.1016/0277-5379(90)90231-h. PMID 2141491.
Gullett NP, Hebbar G, Ziegler TR (April 2010). "Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting". The American Journal of Clinical Nutrition. 91 (4): 1143S–1147S. doi:10.3945/ajcn.2010.28608E. PMC 2844687. PMID 20164318.
Wermers RA, Hurley DL, Kearns AE (December 2004). "Osteoporosis associated with megestrol acetate". Mayo Clinic Proceedings. 79 (12): 1557–1561. doi:10.4065/79.12.1557. PMID 15595341.
Cuerda C, Zugasti A, Bretón I, Camblor M, Miralles P, García P (February 2005). "Treatment with nandrolone decanoate and megestrol acetate in HIV-infected men". Nutrition in Clinical Practice. 20 (1): 93–97. doi:10.1177/011542650502000193. PMID 16207650.
Mulligan K, Zackin R, Von Roenn JH, Chesney MA, Egorin MJ, Sattler FR, et al. (February 2007). "Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial". The Journal of Clinical Endocrinology and Metabolism. 92 (2): 563–570. doi:10.1210/jc.2006-0954. PMID 17090640.
Casaburi R, Nakata J, Bistrong L, Torres E, Rambod M, Porszasz J (November 2015). "Effect of Megestrol Acetate and Testosterone on Body Composition and Hormonal Responses in COPD Cachexia". Chronic Obstructive Pulmonary Diseases. 3 (1): 389–397. doi:10.15326/jcopdf.3.1.2015.0128. PMC 5559120. PMID 28848861.
Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinung M (1997). "Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature". Archives of Internal Medicine. 157 (15): 1651–1656. doi:10.1001/archinte.1997.00440360053005. PMID 9250225.
Chidakel AR, Zweig SB, Schlosser JR, Homel P, Schappert JW, Fleckman AM (February 2006). "High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate". Journal of Endocrinological Investigation. 29 (2): 136–140. doi:10.1007/bf03344086. PMID 16610239. S2CID 25440558.
Bulchandani D, Nachnani J, Amin A, May J (August 2008). "Megestrol acetate-associated adrenal insufficiency". The American Journal of Geriatric Pharmacotherapy. 6 (3): 167–172. doi:10.1016/j.amjopharm.2008.08.004. PMID 18775392.
Marshall LL (September 2003). "Megestrol acetate therapy in geriatric patients: case reviews and associated deep vein thrombosis". The Consultant Pharmacist. 18 (9): 764–773. PMID 16563066.
Foitl DR, Hyman G, Lefkowitch JH (February 1989). "Jaundice and intrahepatic cholestasis following high-dose megestrol acetate for breast cancer". Cancer. 63 (3): 438–439. doi:10.1002/1097-0142(19890201)63:3<438::aid-cncr2820630307>3.0.co;2-o. PMID 2912522. S2CID 35300388.
Gruber T, Dare AO, Balos LL, Lele S, Fenstermaker RA (February 2004). "Multiple meningiomas arising during long-term therapy with the progesterone agonist megestrol acetate. Case report". Journal of Neurosurgery. 100 (2): 328–331. doi:10.3171/jns.2004.100.2.0328. PMID 15086241.
Gruber TJ, Fabiano AJ, Deeb G, Lele SB, Fenstermaker RA (November 2011). "Intracranial meningiomas in patients with uterine sarcoma treated with long-term megestrol acetate therapy". World Neurosurgery. 76 (5): 477.e16–477.e20. doi:10.1016/j.wneu.2011.03.035. PMID 22152580.
Schacter LP, Rozencweig M, Canetta R, Kelley S, Nicaise C, Smaldone L (December 1990). "Overview of hormonal therapy in advanced breast cancer". Seminars in Oncology. 17 (6 Suppl 9): 38–46. PMID 2148026. Archived from the original on 15 November 2021. Retrieved 24 March 2018. Doses [of megestrol acetate] of as high as 1,600 mg/d, given in divided doses three or four times daily, have been given with no clear increase in side effects except for weight gain, mild increases in blood pressure (BP), and some fluid retention.45
Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. (2008). "Classification and pharmacology of progestins". Maturitas. 61 (1–2): 171–180. doi:10.1016/j.maturitas.2008.11.013. PMID 19434889.
Sang GW (April 1994). "Pharmacodynamic effects of once-a-month combined injectable contraceptives". Contraception. 49 (4): 361–385. doi:10.1016/0010-7824(94)90033-7. PMID 8013220.
Toppozada MK (April 1994). "Existing once-a-month combined injectable contraceptives". Contraception. 49 (4): 293–301. doi:10.1016/0010-7824(94)90029-9. PMID 8013216.
Becker H, Düsterberg B, Klosterhalfen H (1980). "[Bioavailability of cyproterone acetate after oral and intramuscular application in men (author's transl)]" [Bioavailability of Cyproterone Acetate after Oral and Intramuscular Application in Men]. Urologia Internationalis. 35 (6): 381–385. doi:10.1159/000280353. PMID 6452729.
Moltz L, Haase F, Schwartz U, Hammerstein J (May 1983). "[Treatment of virilized women with intramuscular administration of cyproterone acetate]" [Efficacy of Intra muscularly Applied Cyproterone Acetate in Hyperandrogenism]. Geburtshilfe und Frauenheilkunde. 43 (5): 281–287. doi:10.1055/s-2008-1036893. PMID 6223851.
Venner PM (December 1990). "Therapeutic options in treatment of advanced carcinoma of the prostate". Seminars in Oncology. 17 (6 Suppl 9): 73–77. PMID 2259929.
Lundgren S, Lønning PE, Utaaker E, Aakvaag A, Kvinnsland S (June 1990). "Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer--I. General findings". Journal of Steroid Biochemistry. 36 (1–2): 99–104. doi:10.1016/0022-4731(90)90118-c. PMID 2362454.
Geller J, Albert J, Geller S (1982). "Acute therapy with megestrol acetate decreases nuclear and cytosol androgen receptors in human BPH tissue". The Prostate. 3 (1): 11–15. doi:10.1002/pros.2990030103. PMID 6176985. S2CID 23541558.
Blumenschein GR (December 1983). "The role of progestins in the treatment of breast cancer". Seminars in Oncology. 10 (4 Suppl 4): 7–10. PMID 6230722.
Alexieva-Figusch J, Blankenstein MA, de Jong FH, Lamberts SW (September 1984). "Endocrine effects of the combination of megestrol acetate and tamoxifen in the treatment of metastatic breast cancer". European Journal of Cancer & Clinical Oncology. 20 (9): 135–140. doi:10.1016/0277-5379(84)90121-4. PMID 6434315.
Endrikat J, Gerlinger C, Richard S, Rosenbaum P, Düsterberg B (December 2011). "Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide". Contraception. 84 (6): 549–557. doi:10.1016/j.contraception.2011.04.009. PMID 22078182.
Smith JA (January 1987). "New methods of endocrine management of prostatic cancer". The Journal of Urology. 137 (1): 1–10. doi:10.1016/s0022-5347(17)43855-9. PMID 3540320.
Venner PM, Klotz PG, Klotz LH, Stewart DJ, Davis IR, Orovan WL, et al. (April 1988). "Megestrol acetate plus minidose diethylstilbestrol in the treatment of carcinoma of the prostate". Seminars in Oncology. 15 (2 Suppl 1): 62–67. PMID 3285485.
Johnson DE, Babaian RJ, Swanson DA, von Eschenbach AC, Wishnow KI, Tenney D (May 1988). "Medical castration using megestrol acetate and minidose estrogen". Urology. 31 (5): 371–374. doi:10.1016/0090-4295(88)90726-1. PMID 3284149.
Geller J (September 1988). "Megestrol acetate and minidose estrogen in prostatic carcinoma". Urology. 32 (3): 281–283. doi:10.1016/0090-4295(88)90402-5. PMID 3413920.
Geller J (February 1991). "Megestrol acetate plus low-dose estrogen in the management of advanced prostatic carcinoma". The Urologic Clinics of North America. 18 (1): 83–91. doi:10.1016/S0094-0143(21)01395-1. PMID 1825145.
Lundgren S, Helle SI, Lonning PE (September 1996). "Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients". Clinical Cancer Research. 2 (9): 1515–1521. PMID 9816328.
Pommier RF, Woltering EA, Fletcher WS (December 1994). "Changes in serum sex steroid levels during megestrol acetate therapy". Surgical Oncology. 3 (6): 351–359. doi:10.1016/0960-7404(94)90074-4. PMID 7773452.
Lønning PE (2009). "Additive endocrine therapy for advanced breast cancer - back to the future". Acta Oncologica. 48 (8): 1092–1101. doi:10.3109/02841860903117816. PMID 19863216. S2CID 26081050.
Eil C, Edelson SK (July 1984). "The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors". The Journal of Clinical Endocrinology and Metabolism. 59 (1): 51–55. doi:10.1210/jcem-59-1-51. PMID 6725525.
Luthy IA, Begin DJ, Labrie F (November 1988). "Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture". Journal of Steroid Biochemistry. 31 (5): 845–852. doi:10.1016/0022-4731(88)90295-6. PMID 2462135.
Poyet P, Labrie F (October 1985). "Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate". Molecular and Cellular Endocrinology. 42 (3): 283–288. doi:10.1016/0303-7207(85)90059-0. PMID 3930312. S2CID 24746807.
Farrar DJ (March 1999). "Megestrol acetate: promises and pitfalls". AIDS Patient Care and STDs. 13 (3): 149–152. doi:10.1089/apc.1999.13.149. PMID 10375262.
Tisell LE, Salander H (February 1975). "Androgenic properties and adrenal depressant activity of megestrol acetate observed in castrated male rats". Acta Endocrinologica. 78 (2): 316–324. doi:10.1530/acta.0.0780316. PMID 1172901.
El Makhzangy MN, Wynn V, Lawrence DM (January 1979). "Sex hormone binding globulin capacity as an index of oestrogenicity or androgenicity in women on oral contraceptive steroids". Clinical Endocrinology. 10 (1): 39–45. doi:10.1111/j.1365-2265.1979.tb03031.x. PMID 571314. S2CID 7262495.
Labrie C, Cusan L, Plante M, Lapointe S, Labrie F (October 1987). "Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer". Journal of Steroid Biochemistry. 28 (4): 379–384. doi:10.1016/0022-4731(87)91054-5. PMID 2444770.
Briggs MH, Briggs M (October 1973). "Glucocorticoid properties of progestogens". Steroids. 22 (4): 555–559. doi:10.1016/0039-128x(73)90011-1. PMID 4747450.
Helle SI, Lundgren S, Geisler S, Ekse D, Holly JM, Lønning PE (July 1999). "Effects of treatment with megestrol acetate on the insulin-like growth factor system: time and dose dependency". European Journal of Cancer. 35 (7): 1070–1075. doi:10.1016/s0959-8049(99)00055-6. PMID 10533450.
Stanczyk FZ (September 2002). "Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception". Reviews in Endocrine & Metabolic Disorders. 3 (3): 211–224. doi:10.1023/A:1020072325818. PMID 12215716. S2CID 27018468.
Goletiani NV, Keith DR, Gorsky SJ (October 2007). "Progesterone: review of safety for clinical studies". Experimental and Clinical Psychopharmacology. 15 (5): 427–444. doi:10.1037/1064-1297.15.5.427. PMID 17924777.
Farinha A, Bica A, Tavares P (May 2000). "Improved bioavailability of a micronized megestrol acetate tablet formulation in humans". Drug Development and Industrial Pharmacy. 26 (5): 567–570. doi:10.1081/ddc-100101270. PMID 10789071. S2CID 24952875.
Gadducci A, Genazzani AR (December 1999). "Endocrine therapy for gynecological cancer". Gynecological Endocrinology. 13 (6): 441–456. doi:10.3109/09513599909167590. PMID 10685337.
Yang YQ, Li SX, Gu XG (August 1985). "[Effect of progestin no. 1 (cymegesolate) on menstrual cycles and plasma levels of progesterone in rhesus monkeys]". Sheng Li Xue Bao (in Chinese). 37 (4): 368–373. PMID 3837333.
Wu JZ, Yun XJ, Wu MZ, Shen HY, Wang AL (February 1983). "[Clinical study of a long-acting progestogen contraceptive 3-cyclopentyl propionate of megestrol acetate (progestin no. 1)]". Sheng Zhi Yu Bi Yun = Reproduction and Contraception (in Chinese). 3 (2): 36–38. PMID 12339176.
Pirzada OL (June 2002). "Effect of megestrol caproate on the reproductive function of laboratory animals". Bulletin of Experimental Biology and Medicine. 133 (6): 574–576. doi:10.1023/A:1020233925626. PMID 12447469. S2CID 24115315.
Cooley G, Kellie AE (October 1964). "Synthesis of [1,2-3H2]medroxyprogesterone acetate (17-alpha-acetoxy-6-alpha-methyl[1,2-3H2]pregn-4-ene-3,20-dione) and [1,2-3H2]megestrol acetate (17-alpha-acetoxy-6-methyl[1,2-3H2]pregna-4,6-diene-3,20-dione)". The Biochemical Journal. 93 (1): 8C–9C. doi:10.1042/bj0930008c. PMID 5320316.
Bakke OM, Wardell WM, Lasagna L (May 1984). "Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: issues of safety". Clinical Pharmacology and Therapeutics. 35 (5): 559–567. doi:10.1038/clpt.1984.78. PMID 6713769. S2CID 7452111.
Kistner RW (1959). "Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium". Cancer. 12 (6): 1106–1122. doi:10.1002/1097-0142(195911/12)12:6<1106::aid-cncr2820120607>3.0.co;2-m. PMID 14409476.
Wait RB (January 1973). "Megestrol acetate in the management of advanced endometrial carcinoma". Obstetrics and Gynecology. 41 (1): 129–136. PMID 4682608.
Lundgren S (1992). "Progestins in breast cancer treatment. A review". Acta Oncologica. 31 (7): 709–722. doi:10.3109/02841869209083859. PMID 1476750.
Taylor SG, Morris RS (January 1951). "Hormones in breast metastasis therapy". The Medical Clinics of North America. 35 (1): 51–61. doi:10.1016/s0025-7125(16)35321-4. PMID 14796108.
Gordon D, Horwitt BN, Segaloff A, Murison PJ, Schlosser JV (March 1952). "Hormonal therapy in cancer of the breast. III. Effect of progesterone on clinical course and hormonal excretion". Cancer. 5 (2): 275–277. doi:10.1002/1097-0142(195203)5:2<275::aid-cncr2820050213>3.0.co;2-h. PMID 14905411.
Stoll BA (August 1967). "Progestin therapy of breast cancer: comparison of agents". British Medical Journal. 3 (5561): 338–341. doi:10.1136/bmj.3.5561.338. PMC 1841969. PMID 6029163.
Ansfield FJ, Davis HL, Ellerby RA, Ramirez G (April 1974). "A clinical trial of megestrol acetate in advanced breast cancer". Cancer. 33 (4): 907–910. doi:10.1002/1097-0142(197404)33:4<907::aid-cncr2820330403>3.0.co;2-y. PMID 4819220. S2CID 45772720.
Pannuti F, Martoni A, Lenaz GR, Piana E, Nanni P (April 1978). "A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate". Cancer Treatment Reports. 62 (4): 499–504. PMID 350387.
Alexieva-Figusch J, van Gilse HA, Hop WC, Phoa CH, Blonk-van der Wijst J, Treurniet RE (December 1980). "Progestin therapy in advanced breast cancer: megestrol acetate--an evaluation of 160 treated cases". Cancer. 46 (11): 2369–2372. doi:10.1002/1097-0142(19801201)46:11<2369::aid-cncr2820461111>3.0.co;2-3. PMID 7438013. S2CID 39767759.
Bines J, Dienstmann R, Obadia RM, Branco LG, Quintella DC, Castro TM, et al. (April 2014). "Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial". Annals of Oncology. 25 (4): 831–836. doi:10.1093/annonc/mdu015. PMID 24615412.
Gutierrez R (August 1949). "New horizons in the surgical management of carcinoma of the prostate gland". American Journal of Surgery. 78 (2): 147–169. doi:10.1016/0002-9610(49)90323-2. PMID 18135629.
Tchekmedyian NS, Tait N, Moody M, Greco FA, Aisner J (December 1986). "Appetite stimulation with megestrol acetate in cachectic cancer patients". Seminars in Oncology. 13 (4 Suppl 4): 37–43. PMID 3798127.
Tchekmedyian NS, Tait N, Moody M, Aisner J (March 1987). "High-dose megestrol acetate. A possible treatment for cachexia". JAMA. 257 (9): 1195–1198. doi:10.1001/jama.1987.03390090067026. PMID 3806918.
Aisner J, Tchekmedyian NS, Tait N, Parnes H, Novak M (April 1988). "Studies of high-dose megestrol acetate: potential applications in cachexia". Seminars in Oncology. 15 (2 Suppl 1): 68–75. PMID 3285486.
Aisner J, Parnes H, Tait N, Hickman M, Forrest A, Greco FA, et al. (December 1990). "Appetite stimulation and weight gain with megestrol acetate". Seminars in Oncology. 17 (6 Suppl 9): 2–7. PMID 2259925.
Porche DJ (1994). "Megestrol acetate oral suspension". The Journal of the Association of Nurses in AIDS Care. 5 (4): 35–6, 44. PMID 7948971.
Romatowski J (March 1989). "Use of megestrol acetate in cats". Journal of the American Veterinary Medical Association. 194 (5): 700–702. PMID 2647696.
Simpson BS, Papich MG (March 2003). "Pharmacologic management in veterinary behavioral medicine". The Veterinary Clinics of North America. Small Animal Practice. 33 (2): 365–404, vii. doi:10.1016/S0195-5616(02)00130-4. PMID 12701517.

ncbi.nlm.nih.gov

Mears E (May 1963). "A new type of oral contraceptive". British Medical Journal. 1 (5341): 1318–1320. doi:10.1136/bmj.1.5341.1318. PMC 2123904. PMID 13934321.
Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S (March 2013). "Megestrol acetate for treatment of anorexia-cachexia syndrome". The Cochrane Database of Systematic Reviews. 2013 (3): CD004310. doi:10.1002/14651858.CD004310.pub3. PMC 6418472. PMID 23543530.
Guise TA, Oefelein MG, Eastham JA, Cookson MS, Higano CS, Smith MR (2007). "Estrogenic side effects of androgen deprivation therapy". Reviews in Urology. 9 (4): 163–180. PMC 2213888. PMID 18231613.
Gullett NP, Hebbar G, Ziegler TR (April 2010). "Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting". The American Journal of Clinical Nutrition. 91 (4): 1143S–1147S. doi:10.3945/ajcn.2010.28608E. PMC 2844687. PMID 20164318.
Casaburi R, Nakata J, Bistrong L, Torres E, Rambod M, Porszasz J (November 2015). "Effect of Megestrol Acetate and Testosterone on Body Composition and Hormonal Responses in COPD Cachexia". Chronic Obstructive Pulmonary Diseases. 3 (1): 389–397. doi:10.15326/jcopdf.3.1.2015.0128. PMC 5559120. PMID 28848861.
Stoll BA (August 1967). "Progestin therapy of breast cancer: comparison of agents". British Medical Journal. 3 (5561): 338–341. doi:10.1136/bmj.3.5561.338. PMC 1841969. PMID 6029163.

dailymed.nlm.nih.gov

"Megace ES- megesterol acetate suspension". DailyMed. 18 March 2014. Retrieved 30 December 2023.

semanticscholar.org

api.semanticscholar.org

Kuhl H (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 (Suppl 1): 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
Zang J, Hou M, Gou HF, Qiu M, Wang J, Zhou XJ, et al. (May 2011). "Antiemetic activity of megestrol acetate in patients receiving chemotherapy". Supportive Care in Cancer. 19 (5): 667–673. doi:10.1007/s00520-010-0886-x. PMID 20419494. S2CID 24567093.
Kauppila A, Kivinen S, Leinonen P, Tuimala R, Vihko R, Ylöstalo P (1983). "Comparison of megestrol acetate and clomiphene citrate as supplemental medication in postmenopausal oestrogen replacement therapy". Archives of Gynecology. 234 (1): 49–58. doi:10.1007/bf02114725. PMID 6660928. S2CID 31075984.
Farish E, Barnes JF, O'Donoghue F, Fletcher CD, Ekevall K, Hart DM (June 2000). "The role of megestrol acetate as an alternative to conventional hormone replacement therapy". Climacteric. 3 (2): 125–134. doi:10.3109/13697130009167614. PMID 11910653. S2CID 19267190.
Ostergaard E (February 1965). "The oral progestational and anti-ovulatory properties of megestrol acetate and its therapeutic use in gynaecological disorders". The Journal of Obstetrics and Gynaecology of the British Empire. 72 (1): 45–48. doi:10.1111/j.1471-0528.1965.tb01372.x. PMID 12332461. S2CID 72608039.
Block M, Bonomi P, Anderson K, Wolter J, Showel J, Pessis D, et al. (1981). "Treatment of stage D prostatic carcinoma with megestrol acetate". Journal of Surgical Oncology. 17 (4): 367–371. doi:10.1002/jso.2930170409. PMID 7265976. S2CID 72595843.
Johnson DE, Kaesler KE, Ayala AG (1975). "Megestrol acetate for treatment of advanced carcinoma of the prostate". Journal of Surgical Oncology. 7 (1): 9–15. doi:10.1002/jso.2930070103. PMID 1177459. S2CID 20882018.
Lebech PE, Nordentoft EL (1967). "A study of endocrine function in the treatment of benign prostatic hypertrophy with megestrol acetate". Acta Obstetricia et Gynecologica Scandinavica. 46 (S9): 25–38. doi:10.3109/00016346709156833. PMID 4169449. S2CID 44780569.
Chidakel AR, Zweig SB, Schlosser JR, Homel P, Schappert JW, Fleckman AM (February 2006). "High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate". Journal of Endocrinological Investigation. 29 (2): 136–140. doi:10.1007/bf03344086. PMID 16610239. S2CID 25440558.
Foitl DR, Hyman G, Lefkowitch JH (February 1989). "Jaundice and intrahepatic cholestasis following high-dose megestrol acetate for breast cancer". Cancer. 63 (3): 438–439. doi:10.1002/1097-0142(19890201)63:3<438::aid-cncr2820630307>3.0.co;2-o. PMID 2912522. S2CID 35300388.
Schindler AE (2015). "Pharmacology of Progestogens". Progestogens in Obstetrics and Gynecology. Springer. pp. 33–40. doi:10.1007/978-3-319-14385-9_2. ISBN 978-3-319-14384-2. S2CID 85844034.
Geller J, Albert J, Geller S (1982). "Acute therapy with megestrol acetate decreases nuclear and cytosol androgen receptors in human BPH tissue". The Prostate. 3 (1): 11–15. doi:10.1002/pros.2990030103. PMID 6176985. S2CID 23541558.
Lønning PE (2009). "Additive endocrine therapy for advanced breast cancer - back to the future". Acta Oncologica. 48 (8): 1092–1101. doi:10.3109/02841860903117816. PMID 19863216. S2CID 26081050.
Poyet P, Labrie F (October 1985). "Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate". Molecular and Cellular Endocrinology. 42 (3): 283–288. doi:10.1016/0303-7207(85)90059-0. PMID 3930312. S2CID 24746807.
El Makhzangy MN, Wynn V, Lawrence DM (January 1979). "Sex hormone binding globulin capacity as an index of oestrogenicity or androgenicity in women on oral contraceptive steroids". Clinical Endocrinology. 10 (1): 39–45. doi:10.1111/j.1365-2265.1979.tb03031.x. PMID 571314. S2CID 7262495.
Stanczyk FZ (September 2002). "Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception". Reviews in Endocrine & Metabolic Disorders. 3 (3): 211–224. doi:10.1023/A:1020072325818. PMID 12215716. S2CID 27018468.
Farinha A, Bica A, Tavares P (May 2000). "Improved bioavailability of a micronized megestrol acetate tablet formulation in humans". Drug Development and Industrial Pharmacy. 26 (5): 567–570. doi:10.1081/ddc-100101270. PMID 10789071. S2CID 24952875.
Pirzada OL (June 2002). "Effect of megestrol caproate on the reproductive function of laboratory animals". Bulletin of Experimental Biology and Medicine. 133 (6): 574–576. doi:10.1023/A:1020233925626. PMID 12447469. S2CID 24115315.
Bakke OM, Wardell WM, Lasagna L (May 1984). "Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: issues of safety". Clinical Pharmacology and Therapeutics. 35 (5): 559–567. doi:10.1038/clpt.1984.78. PMID 6713769. S2CID 7452111.
Ansfield FJ, Davis HL, Ellerby RA, Ramirez G (April 1974). "A clinical trial of megestrol acetate in advanced breast cancer". Cancer. 33 (4): 907–910. doi:10.1002/1097-0142(197404)33:4<907::aid-cncr2820330403>3.0.co;2-y. PMID 4819220. S2CID 45772720.
Alexieva-Figusch J, van Gilse HA, Hop WC, Phoa CH, Blonk-van der Wijst J, Treurniet RE (December 1980). "Progestin therapy in advanced breast cancer: megestrol acetate--an evaluation of 160 treated cases". Cancer. 46 (11): 2369–2372. doi:10.1002/1097-0142(19801201)46:11<2369::aid-cncr2820461111>3.0.co;2-3. PMID 7438013. S2CID 39767759.

seminoncol.org

Schacter LP, Rozencweig M, Canetta R, Kelley S, Nicaise C, Smaldone L (December 1990). "Overview of hormonal therapy in advanced breast cancer". Seminars in Oncology. 17 (6 Suppl 9): 38–46. PMID 2148026. Archived from the original on 15 November 2021. Retrieved 24 March 2018. Doses [of megestrol acetate] of as high as 1,600 mg/d, given in divided doses three or four times daily, have been given with no clear increase in side effects except for weight gain, mild increases in blood pressure (BP), and some fluid retention.45

web.archive.org

Chu YH, Li Q, Zhao ZF (April 1986). "Pharmacokinetics of megestrol acetate in women receiving IM injection of estradiol-megestrol long-acting injectable contraceptive". The Chinese Journal of Clinical Pharmacology. Archived from the original on 25 May 2021. Retrieved 14 August 2019. A radioimmunoassay (RIA), radioligand assay and equilibrium dialysis for determination of plasma and salivary megestrol acetate (MA) concentration, sex hormone binding globulin (SHBG) capacity in plasma and percentage albumin bound MA were studied in healthy women receiving single im injection of estradiol-megestrol long-acting injectable contraceptive. The results showed that after injection the concentration of plasma MA increased rapidly. The meantime of peak plasma MA level was 3rd day, there was a linear relationship between log of plasma MA concentration and time (day) after administration in all subjects, elimination phase half-life t1/2β = 14.35 ± 9.1 days. The plasma sex hormone-binding globulin capacity significantly increased at 7th, 14th day and decreased at 21st, 29th day after injection. The percentage albumin bound MA was 82.4%. There was no specific sex hormone-binding globulin bound MA. There was a positive correlation between the MA concentrations in saliva and those in plasma.
Schacter LP, Rozencweig M, Canetta R, Kelley S, Nicaise C, Smaldone L (December 1990). "Overview of hormonal therapy in advanced breast cancer". Seminars in Oncology. 17 (6 Suppl 9): 38–46. PMID 2148026. Archived from the original on 15 November 2021. Retrieved 24 March 2018. Doses [of megestrol acetate] of as high as 1,600 mg/d, given in divided doses three or four times daily, have been given with no clear increase in side effects except for weight gain, mild increases in blood pressure (BP), and some fluid retention.45

worldcat.org

Ferin J (September 1972). "Effects, Duration of Action and Metabolism in Man". In Tausk M (ed.). Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents. Vol. II. Pergamon Press. pp. 13–24. ISBN 978-0080168128. OCLC 278011135.
Vessey M, Mears E, Andolšek L, Ogrinc-Oven M (1972). "Randomised double-blind trial of four oral progestagen-only contraceptives". The Lancet. 299 (7757): 915–922. doi:10.1016/S0140-6736(72)91492-4. ISSN 0140-6736.
Ringold HJ, Ruelas JP, Batres E, Djerassi C (1959). "Steroids. CXVIII.16-Methyl Derivatives of 17α-Hydroxyprogesterone and of Reichstein's Substance "S"". Journal of the American Chemical Society. 81 (14): 3712–3716. doi:10.1021/ja01523a055. ISSN 0002-7863.
Geisler HE (1973). "The use of megestrol acetate in the treatment of advanced malignant lesions of the endometrium". Gynecologic Oncology. 1 (4): 340–344. doi:10.1016/0090-8258(73)90026-7. ISSN 0090-8258.
Frick J (1973). "Control of spermatogenesis in men by combined administration of progestin and androgen". Contraception. 8 (3): 191–206. doi:10.1016/0010-7824(73)90030-9. ISSN 0010-7824.